Search
Propiomazine
go.drugbank.com/drugs/DB00777ApprovedPropiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia.
Categories: Dopamine D2 Receptor AntagonistsMinaprine
go.drugbank.com/drugs/DB00805ApprovedMinaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.
Esketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigationalThis is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970. … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications
Categories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsElvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalIt was FDA approved on August 27, 2012. On September 24, 2014, the FDA approved the single pill form of elvitegravir. … Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.
Lisuride
go.drugbank.com/drugs/DB00589ApprovedAn ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). … It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period. … [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022.
Mafenide
go.drugbank.com/drugs/DB06795ApprovedVet approvedWithdrawnIn November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements
Valganciclovir
go.drugbank.com/drugs/DB01610ApprovedInvestigationalValganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections.
Thiamine
go.drugbank.com/drugs/DB00152ApprovedInvestigationalNutraceuticalVet approvedThiamine plays an important role in helping the body convert carbohydrates and fat into energy.
Mixtures: CR-FRAN JARABE, DICLOVITH-B-FRTCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigational[A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or … Therefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor.